Virbac Shares Dip to €357.50, Testing 50-Day Moving Average
Midday sees Carros-based veterinary lab Virbac down 1.92% at €357.50, while the SBF 120 drops 0.81%. The stock is moving in a downward Parisian market, weighed down by ongoing tensions in the Middle East and Brent crude rising above $103. Over a year, the stock is still up 16.83%.
A Retreat That Brings the Stock to Its 50-Day Moving Average
Today's decline brings Virbac to its 50-day moving average, located at €357.87, with a negligible gap of -0.10%. However, the price has fallen below its 20-day average (€369.90) by -3.35%. The 200-day average remains at €347.56, which is 2.86% below the current price: the medium-term trend remains bullish. The Bollinger Bands place the stock 13% from the lower channel boundary (lower bound at €353.14, upper bound at €386.66), a setup indicating recent selling pressure and positioning the stock in a potential oversold zone. The RSI at 48 remains neutral. The support identified at €347.50 precisely matches the long-term moving average, making it the most relevant short-term monitoring zone. Resistance is at €384.00. With a negative beta of -0.30 and a monthly volatility of 7.25%, the stock historically moves counter to the broader market: today's session, aligned with the SBF 120's decline, is an exception.
Solid Organic Growth in Q1, Next Update Due End of July
The lab had reported revenue of €384 million in the first quarter of 2026, up 7.7% on a like-for-like and constant currency basis. At actual exchange rates, growth is reduced to 2.2%, highlighting the adverse impact of currency fluctuations on the group's reported performance. More recently, Virbac continued its documentary series dedicated to veterinarians and farmers, focusing on an Iberian pig farm in Extremadura. This communication initiative does not directly affect today's stock price. The financial calendar lists the annual general meeting on June 26, 2026, followed by the Q2 revenue release on July 20. The half-year results are expected on September 17, with an SFAF meeting the following day. Over the past twelve months, the stock has maintained a gain of 16.83% despite a weekly performance of -3.77%. The 50-day moving average, now in contact with the price, remains the technical reference to watch in the coming sessions.
